

Inactivated Vaccine-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/IBB0ECD1484EN.html>

Date: February 2018

Pages: 136

Price: US\$ 3,480.00 (Single User License)

ID: IBB0ECD1484EN

Abstracts

Report Summary

Inactivated Vaccine-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Inactivated Vaccine industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Inactivated Vaccine 2013-2017, and development forecast 2018-2023

Main market players of Inactivated Vaccine in EMEA, with company and product introduction, position in the Inactivated Vaccine market

Market status and development trend of Inactivated Vaccine by types and applications

Cost and profit status of Inactivated Vaccine, and marketing status

Market growth drivers and challenges

The report segments the EMEA Inactivated Vaccine market as:

EMEA Inactivated Vaccine Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Inactivated Vaccine Market: Product Type Segment Analysis (Consumption

Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Pediatrics

Adults

EMEA Inactivated Vaccine Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital

Medical Center

Others

EMEA Inactivated Vaccine Market: Players Segment Analysis (Company and Product introduction, Inactivated Vaccine Sales Volume, Revenue, Price and Gross Margin):

Astellas Pharma (Japan)

CSL Limited (Australia)

Emergent BioSolutions (U.S.)

GlaxoSmithKline (U.K.)

Johnson & Johnson (U.S.)

MedImmune (U.S.)

Merck & Co (U.S.)

Pfizer (U.S.)

Sanofi Pasteur (France)

Serum Institute of India Pvt (India)

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF INACTIVATED VACCINE

- 1.1 Definition of Inactivated Vaccine in This Report
- 1.2 Commercial Types of Inactivated Vaccine
 - 1.2.1 Pediatrics
 - 1.2.2 Adults
- 1.3 Downstream Application of Inactivated Vaccine
 - 1.3.1 Hospital
 - 1.3.2 Medical Center
 - 1.3.3 Others
- 1.4 Development History of Inactivated Vaccine
- 1.5 Market Status and Trend of Inactivated Vaccine 2013-2023
 - 1.5.1 EMEA Inactivated Vaccine Market Status and Trend 2013-2023
 - 1.5.2 Regional Inactivated Vaccine Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Inactivated Vaccine in EMEA 2013-2017
- 2.2 Consumption Market of Inactivated Vaccine in EMEA by Regions
 - 2.2.1 Consumption Volume of Inactivated Vaccine in EMEA by Regions
 - 2.2.2 Revenue of Inactivated Vaccine in EMEA by Regions
- 2.3 Market Analysis of Inactivated Vaccine in EMEA by Regions
 - 2.3.1 Market Analysis of Inactivated Vaccine in Europe 2013-2017
 - 2.3.2 Market Analysis of Inactivated Vaccine in Middle East 2013-2017
 - 2.3.3 Market Analysis of Inactivated Vaccine in Africa 2013-2017
- 2.4 Market Development Forecast of Inactivated Vaccine in EMEA 2018-2023
 - 2.4.1 Market Development Forecast of Inactivated Vaccine in EMEA 2018-2023
 - 2.4.2 Market Development Forecast of Inactivated Vaccine by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole EMEA Market Status by Types
 - 3.1.1 Consumption Volume of Inactivated Vaccine in EMEA by Types
 - 3.1.2 Revenue of Inactivated Vaccine in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in Europe
 - 3.2.2 Market Status by Types in Middle East

- 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Inactivated Vaccine in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Inactivated Vaccine in EMEA by Downstream Industry
- 4.2 Demand Volume of Inactivated Vaccine by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of Inactivated Vaccine by Downstream Industry in Europe
 - 4.2.2 Demand Volume of Inactivated Vaccine by Downstream Industry in Middle East
 - 4.2.3 Demand Volume of Inactivated Vaccine by Downstream Industry in Africa
- 4.3 Market Forecast of Inactivated Vaccine in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF INACTIVATED VACCINE

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Inactivated Vaccine Downstream Industry Situation and Trend Overview

CHAPTER 6 INACTIVATED VACCINE MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

- 6.1 Sales Volume of Inactivated Vaccine in EMEA by Major Players
- 6.2 Revenue of Inactivated Vaccine in EMEA by Major Players
- 6.3 Basic Information of Inactivated Vaccine by Major Players
 - 6.3.1 Headquarters Location and Established Time of Inactivated Vaccine Major Players
 - 6.3.2 Employees and Revenue Level of Inactivated Vaccine Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 INACTIVATED VACCINE MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 Astellas Pharma (Japan)
 - 7.1.1 Company profile
 - 7.1.2 Representative Inactivated Vaccine Product
 - 7.1.3 Inactivated Vaccine Sales, Revenue, Price and Gross Margin of Astellas Pharma

(Japan)

7.2 CSL Limited (Australia)

7.2.1 Company profile

7.2.2 Representative Inactivated Vaccine Product

7.2.3 Inactivated Vaccine Sales, Revenue, Price and Gross Margin of CSL Limited

(Australia)

7.3 Emergent BioSolutions (U.S.)

7.3.1 Company profile

7.3.2 Representative Inactivated Vaccine Product

7.3.3 Inactivated Vaccine Sales, Revenue, Price and Gross Margin of Emergent

BioSolutions (U.S.)

7.4 GlaxoSmithKline (U.K.)

7.4.1 Company profile

7.4.2 Representative Inactivated Vaccine Product

7.4.3 Inactivated Vaccine Sales, Revenue, Price and Gross Margin of GlaxoSmithKline

(U.K.)

7.5 Johnson & Johnson (U.S.)

7.5.1 Company profile

7.5.2 Representative Inactivated Vaccine Product

7.5.3 Inactivated Vaccine Sales, Revenue, Price and Gross Margin of Johnson &

Johnson (U.S.)

7.6 MedImmune (U.S.)

7.6.1 Company profile

7.6.2 Representative Inactivated Vaccine Product

7.6.3 Inactivated Vaccine Sales, Revenue, Price and Gross Margin of MedImmune

(U.S.)

7.7 Merck & Co (U.S.)

7.7.1 Company profile

7.7.2 Representative Inactivated Vaccine Product

7.7.3 Inactivated Vaccine Sales, Revenue, Price and Gross Margin of Merck & Co

(U.S.)

7.8 Pfizer (U.S.)

7.8.1 Company profile

7.8.2 Representative Inactivated Vaccine Product

7.8.3 Inactivated Vaccine Sales, Revenue, Price and Gross Margin of Pfizer (U.S.)

7.9 Sanofi Pasteur (France)

7.9.1 Company profile

7.9.2 Representative Inactivated Vaccine Product

7.9.3 Inactivated Vaccine Sales, Revenue, Price and Gross Margin of Sanofi Pasteur

(France)

7.10 Serum Institute of India Pvt (India)

7.10.1 Company profile

7.10.2 Representative Inactivated Vaccine Product

7.10.3 Inactivated Vaccine Sales, Revenue, Price and Gross Margin of Serum Institute of India Pvt (India)

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF INACTIVATED VACCINE

8.1 Industry Chain of Inactivated Vaccine

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF INACTIVATED VACCINE

9.1 Cost Structure Analysis of Inactivated Vaccine

9.2 Raw Materials Cost Analysis of Inactivated Vaccine

9.3 Labor Cost Analysis of Inactivated Vaccine

9.4 Manufacturing Expenses Analysis of Inactivated Vaccine

CHAPTER 10 MARKETING STATUS ANALYSIS OF INACTIVATED VACCINE

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Inactivated Vaccine-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/IBB0ECD1484EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IBB0ECD1484EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970